563 related articles for article (PubMed ID: 23947935)
21. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter.
Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rosenshtraukh LV; Chazov EI
J Cardiovasc Pharmacol; 2014 Sep; 64(3):247-55. PubMed ID: 24785342
[TBL] [Abstract][Full Text] [Related]
23. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
[TBL] [Abstract][Full Text] [Related]
24. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.
Page RL; Pritchett EL; Connolly S; Wilkinson WE;
J Cardiovasc Electrophysiol; 2008 Feb; 19(2):172-7. PubMed ID: 17916138
[TBL] [Abstract][Full Text] [Related]
25. Dofetilide: a new drug to control cardiac arrhythmia.
Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C
Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593
[TBL] [Abstract][Full Text] [Related]
26. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
Falk RH; Pollak A; Singh SN; Friedrich T
J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
[TBL] [Abstract][Full Text] [Related]
27. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
28. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
Abraham JM; Saliba WI; Vekstein C; Lawrence D; Bhargava M; Bassiouny M; Janiszewski D; Lindsay B; Militello M; Nissen SE; Poe S; Tanaka-Esposito C; Wolski K; Wilkoff BL
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):772-6. PubMed ID: 26063741
[TBL] [Abstract][Full Text] [Related]
29. [Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter].
Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rozenshtraukh LV; Chazov EI
Ter Arkh; 2015; 87(1):38-48. PubMed ID: 25823268
[TBL] [Abstract][Full Text] [Related]
30. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
Glatter K; Yang Y; Chatterjee K; Modin G; Cheng J; Kayser S; Scheinman MM
Circulation; 2001 Jan; 103(2):253-7. PubMed ID: 11208685
[TBL] [Abstract][Full Text] [Related]
31. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study.
Wells R; Khairy P; Harris L; Anderson CC; Balaji S
Pacing Clin Electrophysiol; 2009 Oct; 32(10):1313-8. PubMed ID: 19691680
[TBL] [Abstract][Full Text] [Related]
32. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.
Koene RJ; Menon V; Cantillon DJ; Dresing TJ; Martin DO; Kanj M; Saliba WI; Tarakji KG; Baranowski B; Hussein AA; Tchou PJ; Bhargava M; Callahan TD; Rickard JW; Niebauer MJ; Chung MK; Varma N; Wilkoff BL; Lindsay BD; Wazni OM
Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008168. PubMed ID: 32538135
[TBL] [Abstract][Full Text] [Related]
33. Dofetilide: a new class III antiarrhythmic agent.
Al-Dashti R; Sami M
Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
[No Abstract] [Full Text] [Related]
35. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
[TBL] [Abstract][Full Text] [Related]
36. The safety and efficacy of ibutilide in children and in patients with congenital heart disease.
Hoyer AW; Balaji S
Pacing Clin Electrophysiol; 2007 Aug; 30(8):1003-8. PubMed ID: 17669084
[TBL] [Abstract][Full Text] [Related]
37. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
Trappe HJ; Pfitzner P
Med Klin (Munich); 1996 Oct; 91(10):617-25. PubMed ID: 9019638
[TBL] [Abstract][Full Text] [Related]
38. Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide?
Varriale P; Sedighi A
Clin Cardiol; 2000 Apr; 23(4):265-8. PubMed ID: 10763074
[TBL] [Abstract][Full Text] [Related]
39. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.
Kobayashi Y; Atarashi H; Ino T; Kuruma A; Nomura A; Saitoh H; Hayakawa H
J Cardiovasc Pharmacol; 1997 Sep; 30(3):367-73. PubMed ID: 9300322
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.
Pedersen OD; Bagger H; Keller N; Marchant B; Køber L; Torp-Pedersen C
Circulation; 2001 Jul; 104(3):292-6. PubMed ID: 11457747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
